Browse News
Filter News
Found 361 articles
-
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
-
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
4/16/2024
Palisade Bio, Inc. announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108.
-
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
4/11/2024
Palisade Bio, Inc. announced that it will present at the Virtual Investor Lunch Break Featuring Palisade Bio event on Tuesday, April 16, 2024 at 12:00 PM ET.
-
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
4/10/2024
Palisade Bio, Inc. today announced that it presented at IBD Innovate: Product Development for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA.
-
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
4/9/2024
Vistagen today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD).
-
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
4/7/2024
Arrowhead Pharmaceuticals, Inc. presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe hypertriglyceridemia.
-
Palisade Bio Announces 1-for-15 Reverse Stock Split
4/3/2024
Palisade Bio, Inc. announced a 1-for-15 reverse split of its common stock, par value $0.01, effective at 5:00 PM ET on Friday April 5, 2024.
-
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
4/1/2024
Vistagen today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).
-
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
3/27/2024
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.
-
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
3/25/2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS).
-
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
2/15/2024
Palisade Bio, Inc. announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.
-
Palisade Bio Provides Corporate Update and Reiterates Guidance
2/13/2024
Palisade Bio, Inc. today provided a corporate update and reiterated upcoming milestones.
-
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
2/13/2024
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.
-
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
2/8/2024
Palisade Bio, Inc. today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB).
-
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
2/8/2024
Palisade Bio, Inc. today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB).
-
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
1/30/2024
Palisade Bio, Inc. announced an agreement between the Company and several accredited investors to exercise certain existing warrants to purchase up to an aggregate of 3,413,286 shares of common stock.
-
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
1/29/2024
Palisade Bio, Inc. today announced the presentation of positive preclinical data of its lead asset, PALI-2108 at the Crohn’s & Colitis Congress, which was held on January 25-27, 2024 in Las Vegas, NV.
-
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
1/9/2024
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held January 25-27, 2024 in Las Vegas, NV.
-
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
12/28/2023
Palisade Bio, Inc. announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program.
-
MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office
11/14/2023
Institute of Biomedical Research Corp., a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence, is pleased to provide the following update: